Ashish Ranjan Dwivedi
Ashish Ranjan Dwivedi publishes mostly in Organic Chemistry, Molecular Biology and Pharmacology, on topics such as Synthesis and biological activity, Cholinesterase and Neurodegenerative Diseases and Computational Drug Discovery Methods.
- World rank
- #1,069,774 of 7,710,434 ranked researchers
- Rank in India
- #15,255 of 280,097
- Works
- 77
- Citations
- 1.4k
- Citations per work
- 18.3
What does Ashish Ranjan Dwivedi research?
Ashish Ranjan Dwivedi's work is mostly in Chemistry (40%), Biochemistry, Genetics and Molecular Biology (13%), Medicine (12%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences3545.4%
- Chemistry3139.8%
- Computer Science45.6%
- Everything else1822.9%
- Life Sciences1520.0%
- Health Sciences911.7%
- Medicine911.7%
- 1Organic Chemistry40% of their works
- 2Molecular Biology13% of their works
- 3Pharmacology12% of their works
- 4Computational Theory and Mathematics6% of their works
- 5Immunology4% of their works
- 6Plant Science3% of their works
Research topics
- Synthesis and biological activity
- Cholinesterase and Neurodegenerative Diseases
- Computational Drug Discovery Methods
- Click Chemistry and Applications
- Synthesis and Biological Evaluation
- Multicomponent Synthesis of Heterocycles
- Quinazolinone synthesis and applications
- Synthesis and Characterization of Heterocyclic Compounds
Which keywords describe Ashish Ranjan Dwivedi's research?
The keywords of their largest research topics: Medicinal Chemistry, Anticancer Agents, Heterocyclic Compounds, Tubulin Inhibitors, Vascular Targeting Agents, Drug Discovery, Biological Evaluation and Synthesis.
- Scaffold
- Quinazoline
- Indirubin
- Antimicrobial Activity
- Click Chemistry
- Drug Target Identification
- Anticancer
- Cholinesterase Inhibitors
- Synthesis
- Drug Discovery
- Tubulin Inhibitors
- Anticancer Agents
- Medicinal Chemistry
- Heterocyclic Compounds
- Vascular Targeting Agents
- Biological Evaluation
- Acetylcholinesterase
- Molecular Docking
- Antimicrobial
- Virtual Screening
- Copper-Catalyzed Cycloaddition
- Green Chemistry
- Multicomponent Reactions
- Quinoxaline
- Triazines
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most.
All 25 words, with their numbers
- Medicinal Chemistry383 topics
- Anticancer Agents272 topics
- Heterocyclic Compounds272 topics
- Tubulin Inhibitors211 topic
- Vascular Targeting Agents211 topic
- Drug Discovery203 topics
- Biological Evaluation173 topics
- Synthesis173 topics
- Acetylcholinesterase161 topic
- Cholinesterase Inhibitors161 topic
- Molecular Docking162 topics
- Anticancer112 topics
- Antimicrobial112 topics
- Drug Target Identification111 topic
- Virtual Screening111 topic
- Click Chemistry91 topic
- Copper-Catalyzed Cycloaddition91 topic
- Antimicrobial Activity61 topic
- Green Chemistry61 topic
- Indirubin61 topic
- Multicomponent Reactions61 topic
- Quinazoline61 topic
- Quinoxaline61 topic
- Scaffold51 topic
- Triazines51 topic
Where does Ashish Ranjan Dwivedi work?
Ashish Ranjan Dwivedi's main affiliation in the publication record is GITAM University, India.
How many publications and citations does Ashish Ranjan Dwivedi have?
OpenAlex counts 77 works and 1,406 citations for Ashish Ranjan Dwivedi, an h-index of 19, ranking #1,069,774 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Ashish Ranjan Dwivedi. Posts are plain text and can be reported.